Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination

Elena Winheim, Tabea Eser, Flora Deák, Mohamed I. M. Ahmed, Olga Baranov, Linus Rinke, Katharina Eisenächer, Antonio Santos-Peral, Hadi Karimzadeh, Michael Pritsch, Clemens Scherer, Maximilian Muenchhoff, Johannes C. Hellmuth, Michael von Bergwelt-Baildon, Laura Olbrich, Michael Hoelscher, Andreas Wieser, Inge Kroidl, Simon Rothenfusser, Christof Geldmacher, Anne B. Krug (2022 Nov 20) Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination. Eur J Immunology. doi: 10.1002/eji.202250090. PMID: 36404054

Abstract cited from the article:

Dysregulation of the myeloid cell compartment is a feature of severe disease in hospitalized COVID-19 patients. Here, we investigated the response of circulating dendritic cell (DC) and monocyte subpopulations in SARS-CoV-2 infected outpatients with mild disease and compared it to the response of healthy individuals to yellow fever vaccine virus YF17D as a model of a well-coordinated response to viral infection. In SARS-CoV-2-infected outpatients circulating DCs were persistently reduced for several weeks whereas after YF17D vaccination DC numbers were decreased temporarily and rapidly replenished by increased proliferation until 14 days after vaccination. The majority of COVID-19 outpatients showed high expression of CD86 and PD-L1 in monocytes and DCs early on, resembling the dynamic after YF17D vaccination. In a subgroup of patients, low CD86 and high PD-L1 expression were detected in monocytes and DCs coinciding with symptoms, higher age, and lower lymphocyte counts. This phenotype was similar to that observed in severely ill COVID-19 patients, but less pronounced. Thus, prolonged reduction and dysregulated activation of blood DCs and monocytes were seen in a subgroup of symptomatic non-hospitalized COVID-19 patients while a transient coordinated activation was characteristic for the majority of patients with mild COVID-19 and the response to YF17D vaccination.